Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,924 recruiting studies in this area right now.
By phase
- Not applicable2,025
- Phase 21,074
- Phase 1791
- Phase 1/Phase 2480
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama157
- Maryland152
- Arizona126
- Florida104
- Massachusetts104
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,924 total
- NCT07010237RecruitingPhase 2
Lower-dose immune therapy plus hetrombopag for older adults with severe aplastic anemia
This trial tests a milder version of immunosuppressive therapy combined with hetrombopag (a drug that helps bone marrow make blood cells) in people aged 65 years and older with severe aplastic anemia. The goal is to see if this approach is both safer and effective for older patients.
Tianjin, Tianjin MunicipalityAges 65 years+ - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07003568RecruitingPhase 1
CAR-T cell therapy for multiple myeloma with bone or organ spread
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread outside the bone marrow (extramedullary disease). The goal is to see if this dual-target approach can attack the cancer more effectively.
ShanghaiAges 18–75 - NCT07013435Recruiting
Resilience training for lymphoma survivors
This study tests a program to help lymphoma survivors build resilience and improve long-term quality of life after treatment. It's a behavioral intervention, not a drug trial, that focuses on coping and well-being.
Boston, MassachusettsAges 18 years+ - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT07008261Recruiting
Robot-assisted bladder removal surgery study
This study is for people who are scheduled to have their bladder removed (radical cystectomy). It looks at whether using a robot helps with blood loss, pain, and the need for blood transfusions during and after surgery.
Frankfurt am MainAges 18 years+ - NCT07007052RecruitingPhase 2
Tagraxofusp plus venetoclax for newly diagnosed BPDCN
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
AmiensAges 18 years+ - NCT07011316Recruiting
Preventing lymphedema in cancer patients through monitoring
This trial tests whether a simple standing test can help spot early signs of lymphedema (swelling) in cancer patients. If you are being treated at the Greater Poland Cancer Centre, you may be able to help doctors learn how to prevent this side effect.
Poznan, Greater Poland VoivodeshipAges 18 years+ - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06999954Recruiting
Global survey for Shwachman-Diamond syndrome and related conditions
This trial is a global survey and registry for people with Shwachman-Diamond Syndrome and related inherited blood disorders. It aims to connect patients, families, and researchers to better understand these conditions and improve care.
Woburn, MassachusettsAges Any age - NCT06999031RecruitingEarly Phase 1
CG-105-12 for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Nanchang, JiangxiAges 18–75 - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06130579RecruitingPhase 2
Interferon-α for TP53-mutated blood cancer after transplant
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT06390306Recruiting
Combination therapy for advanced CML
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Duarte, CaliforniaAges 12 years+ - NCT06998524RecruitingPhase 3
Testing emicizumab for type 3 von Willebrand disease
This study tests whether emicizumab can help prevent or treat bleeding episodes in people with type 3 von Willebrand disease, a rare and severe bleeding disorder. It may offer a new option for those who have not had good control with standard treatments.
Sacramento, CaliforniaAges 1 month+ - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06846489RecruitingPhase 2
Acalabrutinib plus rituximab for untreated mantle cell lymphoma
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT06997081RecruitingPhase 2
ERd combination for newly diagnosed multiple myeloma
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Miami, FloridaAges 18 years+ - NCT07001189Recruiting
Numbing for sickle cell pain crisis: a study
This trial tests whether numbing a specific area (regional anesthesia) can reduce inflammation and pain during a sickle cell pain crisis. It may offer a new way to manage severe pain without strong medications.
Pointe-à-PitreAges 18 years+ - NCT06994169Recruiting
Glofitamab treatment study for relapsed DLBCL
This study looks at how well glofitamab works in real-world patients with a type of lymphoma that has come back or not responded to treatment. It includes adults who have already received obinutuzumab and at least one dose of glofitamab in a special access program.
ArgenteuilAges 18 years+ - NCT07002099RecruitingPhase 2
Selinexor, methotrexate, and rituximab with radiation for new CNS lymphoma
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
SuzhouAges 18 years+ - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,924 recruiting hematology studies from the U.S. registry right now, out of 7,354 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.